The interaction of plasma renin activity and plasma atrial natriuretic peptide in 21-hydroxylase deficiency patients

Journal of Endocrinological Investigation

Volumn 28, Issue 6, 2005, Pages 300-304

  Germano, C M R ^a   De Castro, M ^a   Crescencio, J C ^a   Gallo Jr , L ^a   Antunes Rodrigues, J ^a   Moreira, A C ^a   Elias, L L K ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

21 Hydroxylase deficiency; Atrial natriuretic peptide; Plasma renin activity

Indexed keywords

ALDOSTERONE; ANGIOTENSIN II; ATRIAL NATRIURETIC FACTOR; CORTICOSTEROID; NATRIURETIC FACTOR; RENIN; STEROID 21 MONOOXYGENASE;

ADOLESCENT; ADULT; ARTICLE; BLOOD ANALYSIS; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GROUPS BY AGE; HEAD TILTING; HOMEOSTASIS; HUMAN; MALE; PLASMA RENIN ACTIVITY; PROTEIN PROTEIN INTERACTION; RECUMBENCY; SITTING; STEROID 21 MONOOXYGENASE DEFICIENCY; BLOOD; BODY POSTURE; CASE CONTROL STUDY; CONGENITAL ADRENAL HYPERPLASIA; PATHOPHYSIOLOGY; PHYSIOLOGY; REFERENCE VALUE;

ADOLESCENT; ADRENAL CORTEX HORMONES; ADRENAL HYPERPLASIA, CONGENITAL; ADULT; ATRIAL NATRIURETIC FACTOR; CASE-CONTROL STUDIES; FEMALE; HUMANS; MALE; POSTURE; REFERENCE VALUES; RENIN; STEROID 21-HYDROXYLASE;

EID: 23444439200     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03347194     Document Type: Article

References (36)

1. Speiser FW, Dupont J, Zhu D, et al. Disease expression and molecular genotype in congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Invest 1992, 90: 584-95.
2. White PC, Speiser PW. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Endocr Rev 2000, 21: 245-91.
3. Hughes IA. Congenital adrenal hyperplasia--a continuum of disorders. Lancet 1998, 352: 752-4.
4. Oetliker OH, Zurbrugg RP. Renal regulation of fluid, electrolyte and acid-base homeostasis in the salt-losing syndrome of congenital adrenal hyperplasia (SL-CAH). ECF volume: a compensatory factor in aldosterone deficiency. J Clin Endocrinol Metab 1978, 46: 543-51.
5. Joint LWPES/ESPE CAH Working group. Consensus statement on 21-hydroxylase deficiency from the Lawson Wilkins Pediatric Endocrine Society and the European Society for Paediatric Endocrinology. J Clin Endocrinol Metab 2002, 87: 4048-53.
6. Rosier A, Levine LS, Schneider B, Novogroder M, New MI. The interrelationship of sodium balance, plasma renin activity and ACTH in congenital adrenal hyperplasia. J Clin Endocrinol Metab 1977, 45: 500-12.
7. Grant DB, Dillon MJ, Atherden SM, Levinsky RJ. Congenital adrenal hyperplasia: renin and steroid values during treatment. Eur J Pediatr 1977, 126: 86-96.
8. Hughes IA, Wilton A, Lole CA, Gray OP. Continuing need for mineralocorticoid therapy in salt-losing congenital adrenal hyperplasia. Arch Dis Child 1979, 54: 350-5.
9. Jansen M, Wit JM, van den Brande JL. Reinstitution of mineralocorticoid therapy in congenital adrenal hyperplasia. Effects on control and growth. Acta Paediatr Scand 1981, 70: 229-33.
10. Griffiths KD, Anderson JM, Rudd BT, Virdi NK, Holder G, Rayner PH. Plasma renin activity in the management of congenital adrenal hyperplasia. Arch Dis Child 1984, 59: 360-5.
11. Arisaka O, Hosaka A, Arisaka M, et al. Atrial natriuretic peptide and fludrocortisone therapy in congenital adrenal hyperplasia. Acta Paediatr 1992, 81: 268-9.
12. Kruger C, Hoper K, Weissortel R, Hensen J, Dorr HG. Value of direct measurement of active renin concentrations in congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Eur J Pediatr 1996, 155: 858-61
13. Levine LS. Congenital adrenal hyperplasia. Pediatr Rev 2000, 21: 159-70.
14. Brenner BM, Ballermann BJ, Gunning ME, Zeidel ML. Diverse biological actions of atrial natriuretic peptide. Physiol Rev 1990, 70: 665-99.
15. McCann SM, Antunes-Rodrigues J, Jankowski M, Gutkowska J. Oxytocin, vasopressin and atrial natriuretic peptide control body fluid homeostasis by action on their receptors in brain, cardiovascular system and kidney. Prog Brain Res 2002, 139: 309-28.
16. Cohen N, Gilbert R, Wirth A, Casley D, Jerums G. Atrial natriuretic peptide and plasma renin levels in assessment of mineralocorticoid replacement in Addison's disease. J Clin Endocrinol Metab 1996, 81: 1411-5.
17. Gutkowska J, Bourassa M, Roy D, et al. Immunoreactive atrial natriuretic factor (IR-ANF) in human plasma. Biochem Biophys Res Commun 1984, 128: 1350-7.
18. Flad T, Conway JD. The role of plasma renin activity in evaluating the adequacy of mineralocorticoid replacement in primary adrenal insufficiency. Clin Endocrinol (Oxf) 1996, 45: 529-34.
19. Lopes LA, Dubuis JM, Vallotton MB, Sizonenko PC. Should we monitor more closely the dosage of 9 alpha-fluorohydrocortisone in salt-losing congenital adrenal hyperplasia? J Pediatr Endocrinol Metab 1998, 11: 733-7.
20. Hughes IA. Monitoring treatment in congenital adrenal hyperplasia. Arch Dis Child 1990, 65: 333.
21. Oelkers W, Diederich S, Bahr V. Diagnosis and therapy surveillance in Addison's disease: rapid adrenocorticotropin (ACTH) test and measurement of plasma ACTH, renin activity, and aldosterone. J Clin Endocrinol Metab 1992, 75: 259-64.
22. Goldsmith SR, Francis, GS, Cohn, JN. Effect of head-down tilt on basal plasma norepinephrine and renin activity in humans. J Appl Physiol 1985, 59: 1068-71.
23. Hodsman GP, Tsunoda K, Ogawa K, Johnston CI. Effects of posture on circulating atrial natriuretic peptide. Lancet 1985, 2: 1427.
24. Ledsome Jr, Wilson N, Courneya CA, Rankin AJ. Release of atrial natriuretic peptide by atrial distension. Can J Physiol Pharmacol 1985, 63: 739-42.
25. Judith AM, Sheldon WB, Skorechi KL Control of extracellular fluid volume. In: Brenner BM and Rector FC Jr eds. The kidney. Philadelphia: WB Saunders Company, 2001: 817-72.
26. Dibona GF. Peripheral and central interactions between the renin-angiotensin system and the renal sympathetic nerves in control of renal function. Ann NY Acad Sci 2001, 940: 395-406.
27. Bornstein SR, Breidert M, Ehrhart-Bornstein M, Kloos B, Scherbaum WA. Plasma catecholamines in patients with Addison's disease. Clin Endocrinol 1995, 42: 215-8.
28. Merke DP, Chrousos GP, Eisenhofer G, et al. Adrenomedullary dysplasia and hypofunction in patients with classic 21-hydroxylase deficiency. N Engl J Med 2000, 343: 1362-8.
29. Floras JS. Sympathoinhibitory effects of atrial natriuretic factor in normal humans. Circulation 1990, 81: 1860-73.
30. Antunes-Rodrigues J, de Castro M, Elias LL, Valenca MM, McCann SM. Neuroendocrine control of body fluid metabolism. Physiol Rev 2004, 84: 169-208.
31. Hodsman GP, Phillips PA, Ogawa K, Johnston CI. Atrial natriuretic factor in normal man: effects of tilt, posture, exercise and haemorrhage. J Hypertens 1986, 4 (Suppl): S503-5.
32. Anderson JV, Donckier J, Mckenna WJ, Bloom SR. The plasma release of atrial natriuretic peptide in man. Clin Sci 1986, 1: 151-5.
33. Solomon LR, Atherton JC, Bobinski H, Green R. Effect of posture on plasma immunoreactive atrial natriuretic peptide concentrations in man. Clin Sci 1986, 71: 299-305.
34. Peterson C, Madsen B, Perlman A, Chan AY, Myers BD. Atrial natriuretic peptide and the renal response to hypervolemia in nephrotic humans. Kidney Int 1988, 34: 825-31.
35. Fried T, Aronoff GR, Benabe JE, et al. Renal and hemodynamic effects of atrial natriuretic peptide in patients with cirrhosis. Am J Med Sci 1990, 299: 2-9.
36. Frisch H, Battelino T, Schober E, et al. Salt wasting in simple virilizing congenital adrenal hyperplasia. J Pediatr Endocrinol Metab 2001, 14: 1649-55.